Form 4 for IRD Opus Genetics, Inc.
Accepted 2026-03-18 00:00:00 ET · period of report 2026-03-16 · accession 0000905148-26-001380 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-18 | 2026-03-16 | IRD | Jayagopal Ashwath | Chief Scientific, Dev. Ofc | S - Sale | $5.12 | -3,719 | 516.8K | -0.7% | -$19.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-16 | S | D | 3,719 | $5.12 | 516,775 | D | — | — | (F2) The price in column 4 represents the weighted average price. The shares were sold in multiple transactions at prices ranging from $5.11 to $5.1301, inclusive. The Reporting Person undertakes to provide the issuer, any securityholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |